ArticleHip & pelvis2026
Predictors of In-Hospital Mortality, Cost, and Length of Stay following Periprosthetic Fracture of the Hip.
Article in Hip & pelvis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The frequency of total hip arthroplasty (THA) has increased significantly. The morbidity and economic burden of periprosthetic hip fractures (PPHFx) following THA is high. The objective of this study is to identify predictors of in-hospital mortality, length of stay (LOS), and hospital costs associated with PPHFx. Materials and Methods: A retrospective analysis of the National Inpatient Sample (NIS) for all patients diagnosed with periprosthetic fracture around the internal prosthetic hip joint (International Classification of Disease, Tenth Revision, Clinical Modification [ICD-10-CM], M97.01XA, and M97.02XA) between 2016 and 2019 was conducted. Predictors of outcomes following PPHFx were assessed using univariable analyses; those with a Results: The study included 77,565 patient encounters. Significant predictors of in-hospital mortality included age, female sex, and comorbidities, such as metastatic cancer and liver disease. Predictors of increased LOS included black race, comorbidities, such as paralysis and fluid and electrolyte disorders, primary payment source, household income, hospital size, and type. Hospital costs showed an association with race, comorbidities, hospital type, and procedure. Conclusion: In the setting of PPHFx, higher comorbidity, particularly fluid and electrolyte, paralysis, and metastatic cancer, showed an association with all three outcome variables. In addition to comorbidity, advanced age, particularly nonagenarians, showed an association with in-hospital mortality, while cost was primarily driven by the procedure performed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.